

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claims 1-23 (canceled)**

24. (previously added) An isolated amino-terminally truncated MCP-2 comprising residues 2-76 of an MCP-2 polypeptide according to SEQ ID NO: 2, wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residue 1 and has chemokine antagonistic activity.
25. (previously added) An isolated amino-terminally truncated MCP-2 comprising residues 3-76 of an MCP-2 polypeptide according to SEQ ID NO: 2, wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-2 and has chemokine antagonistic activity.
26. (previously added) An isolated amino-terminally truncated MCP-2 comprising residues 4-76 of an MCP-2 polypeptide according to MCP-2 (SEQ ID NO: 2), wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-3 and has chemokine antagonistic activity.
27. (previously added) An isolated amino-terminally truncated MCP-2 polypeptide comprising residues 5-76 of an MCP-2 polypeptide according to SEQ ID NO: 2 or 5, wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-4

and has chemokine antagonistic activity.

28. (cancelled)
29. (cancelled)
30. (cancelled)
31. (new) An isolated amino-terminally truncated MCP-2 polypeptide comprising residues 6-76 of an MCP-2 polypeptide according to SEQ ID NO: 2 or 5, wherein the truncated MCP-2 polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-5 and has chemokine antagonistic activity.
32. (new) The isolated amino-terminally truncated MCP-2 polypeptide of claims 24-27 and 31, wherein the truncated MCP-2 polypeptide is in glycosylated form.
33. (new) A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to any one of claims 24-27 and 31, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
34. (new) The pharmaceutical composition according to claim 29, wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.